Ret-he level in CKD patients receiving ESA

Ret-he level in CKD patients receiving ESA.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220304001

Enrollment

140

Registered

2022-03-04

Start date

2022-01-11

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD who receiving erythropoietin stimulating agent. Ret-He, ESRD, functional iron deficiency anemia

Interventions

Patients who meet the criteria for functional iron deficiency anemia will receive intravenous iron supplement for 2 or 3 months. Then, we evaluate the raising of Hb, Hct after treatment.

Experimental Drug

intravenous iron

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ESRD patients who receiving erythropoietin stimulating agent 2. Hb less than 11 g/dL 3. Tsat less than 30

Exclusion criteria

Exclusion criteria: 1. Patients who are receiving intravenous iron 2.patient who has been diagnosed thalassemia and need regular blood transfusion 3. patient who has blood loss more than 500 ml during the follow up period 4. patients with liver disease 5. patients with other cancers

Design outcomes

Primary

Measure	Time frame
Ret-He 3 months a blood test	—

Secondary

Measure	Time frame
after treat Hb 3 months a blood test	—

Contacts

Public Contactsaranya pongudom

udonthani hospital

saranya.pongudom@gmail.com0817174129

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026